Germany’s IQWiG Pans Sanofi’s Lyxumia For Wrong Comparator Choices
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi’s failure to align its comparator selection with that of Germany’s reimbursement authorities has resulted in dismissal of Lyxumia for diabetes type 2, although the company will have an opportunity to challenge the decision.